Sarah Q To1, Edmond M Kwan2, Heidi C Fettke1, Andrew Mant3, Maria M Docanto1, Luciano Martelotto1, Patricia Bukczynska1, Nicole Ng4, Lisa-Jane K Graham5, Phillip Parente6, Carmel Pezaro6, Kate Mahon7, Lisa Horvath8, Tilman Todenhöfer9, Arun A Azad10. 1. Department of Medicine, School of Clinical Sciences, Monash University, Australia. 2. Department of Medicine, School of Clinical Sciences, Monash University, Australia; Department of Medical Oncology, Monash Health, Australia. 3. Medical Oncology Unit, Eastern Health, Australia. 4. Department of Medical Oncology, Monash Health, Australia. 5. Medical Oncology, Chris O'Brien Lifehouse, Australia. 6. Medical Oncology Unit, Eastern Health, Australia; Eastern Health Clinical School, Monash University, Australia. 7. Medical Oncology, Chris O'Brien Lifehouse, Australia; Garvan Institute of Medical Research, Australia. 8. Medical Oncology, Chris O'Brien Lifehouse, Australia; Garvan Institute of Medical Research, Australia; Royal Prince Alfred Hospital, Australia; University of Sydney, Australia. 9. Department of Urology, Eberhard-Karls-University Tuebingen, Germany. 10. Department of Medicine, School of Clinical Sciences, Monash University, Australia; Department of Medical Oncology, Monash Health, Australia. Electronic address: arun.azad@monash.edu.
Abstract
In 2014, a landmark study was published demonstrating that the expression of androgen receptor splice variant (AR-V) 7 was a negative predictive biomarker for response to abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) patients. However, these results were not supported by the recently reported ARMOR3-SV phase III clinical trial, which employed an identical circulating tumour cell assay to assess AR-V7 expression. Therefore, the predictive utility of AR-V7 expression in mCRPC remains uncertain, as does any potential association between other AR-Vs and treatment response. To further investigate, we designed a highly sensitive and specific whole blood assay for detecting AR-V7 and AR-V9. We then examined for a correlation between baseline AR-V7/V9 status and treatment outcome in 37 mCRPC patients commencing abiraterone or enzalutamide. Of the patients, 24% (9/37) were AR-V-positive. Notably, prostate-specific antigen (PSA) response rates did not significantly differ between AR-V-positive (6/9) and AR-V-negative (18/28) patients (66% vs 64%, p=0.9). Likewise, median PSA progression-free survival was not significantly different between AR-V-positive and AR-V-negative patients (9.2 mo vs not reached; p=0.9). These data, which support the findings of the pivotal ARMOR3-SV clinical trial, suggest that baseline AR-V expression does not predict outcomes in mCRPC patients receiving abiraterone or enzalutamide. PATIENT SUMMARY: Detection of androgen receptor splice variants (AR-Vs) in circulating tumour cells of advanced prostate cancer patients has been linked to resistance to abiraterone and enzalutamide. We designed a blood test to detect AR-Vs that can be performed more routinely than tests involving circulating tumour cells and found that patients with AR-Vs still benefit from these effective treatments.
In 2014, a landmark study was published demonstrating that the expression of androgen receptor splice variant (AR-V) 7 was a negative predictive biomarker for response to abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) patients. However, these results were not supported by the recently reported ARMOR3-SV phase III clinical trial, which employed an identical circulating tumour cell assay to assess AR-V7 expression. Therefore, the predictive utility of AR-V7 expression in mCRPC remains uncertain, as does any potential association between other AR-Vs and treatment response. To further investigate, we designed a highly sensitive and specific whole blood assay for detecting AR-V7 and AR-V9. We then examined for a correlation between baseline AR-V7/V9 status and treatment outcome in 37 mCRPC patients commencing abiraterone or enzalutamide. Of the patients, 24% (9/37) were AR-V-positive. Notably, prostate-specific antigen (PSA) response rates did not significantly differ between AR-V-positive (6/9) and AR-V-negative (18/28) patients (66% vs 64%, p=0.9). Likewise, median PSA progression-free survival was not significantly different between AR-V-positive and AR-V-negative patients (9.2 mo vs not reached; p=0.9). These data, which support the findings of the pivotal ARMOR3-SV clinical trial, suggest that baseline AR-V expression does not predict outcomes in mCRPC patients receiving abiraterone or enzalutamide. PATIENT SUMMARY: Detection of androgen receptor splice variants (AR-Vs) in circulating tumour cells of advanced prostate cancerpatients has been linked to resistance to abiraterone and enzalutamide. We designed a blood test to detect AR-Vs that can be performed more routinely than tests involving circulating tumour cells and found that patients with AR-Vs still benefit from these effective treatments.
Authors: Kristina Stuopelyte; Rasa Sabaliauskaite; Arnas Bakavicius; Benedikta S Haflidadóttir; Tapio Visakorpi; Riina-Minna Väänänen; Chintan Patel; Daniel C Danila; Hans Lilja; Juozas R Lazutka; Albertas Ulys; Feliksas Jankevicius; Sonata Jarmalaite Journal: J Urol Date: 2020-02-18 Impact factor: 7.450
Authors: Edmond M Kwan; Heidi Fettke; Megan Crumbaker; Maria M Docanto; Sarah Q To; Patricia Bukczynska; Andrew Mant; Nicole Ng; Siavash Foroughi; Lisa-Jane K Graham; Anne-Maree Haynes; Sarah Azer; Lisi Elizabeth Lim; Eva Segelov; Kate Mahon; Ian D Davis; Phillip Parente; Carmel Pezaro; Tilman Todenhöfer; Niranjan Sathianathen; Christine Hauser; Lisa G Horvath; Anthony M Joshua; Arun A Azad Journal: Transl Androl Urol Date: 2021-04
Authors: Yu Jen Jan; Junhee Yoon; Jie-Fu Chen; Pai-Chi Teng; Nu Yao; Shirley Cheng; Amber Lozano; Gina C Y Chu; Howard Chung; Yi-Tsung Lu; Pin-Jung Chen; Jasmine J Wang; Yi-Te Lee; Minhyung Kim; Yazhen Zhu; Beatrice S Knudsen; Felix Y Feng; Isla P Garraway; Allen C Gao; Leland W K Chung; Michael R Freeman; Sungyong You; Hsian-Rong Tseng; Edwin M Posadas Journal: Theranostics Date: 2019-04-13 Impact factor: 11.556
Authors: Sarennya Pathmanandavel; Megan Crumbaker; Andrew O Yam; Andrew Nguyen; Christopher Rofe; Elizabeth Hovey; Craig Gedye; Edmond M Kwan; Christine Hauser; Arun A Azad; Peter Eu; Andrew J Martin; Anthony M Joshua; Louise Emmett Journal: J Nucl Med Date: 2021-07-29 Impact factor: 10.057